Leadership Team Visionaries. Leaders.
 |
Jeffrey P. McMullenChief Executive OfficerMr. McMullen’s experience in the drug development industry spans more than 30 years. He spent 13 years with major contract research organizations as Vice President of Business Development and Director of Clinical Research, and 9 years at Sterling Drug in the clinical, regulatory, and drug metabolism areas. Mr. McMullen also has extensive international experience including Europe, Japan, South America, and Asia. Mr. McMullen is focused on the continued growth and global expansion of the organization. |
|
 |
Robin C. SheldrickExecutive Vice President, Human ResourcesMs. Sheldrick has worked for more than 20 years in the contract research industry. Her experience includes a combination of clinical research and human resources. As head of human resources, Ms. Sheldrick has global responsibility for employee recruitment and retention, compensation and benefits, employee relations, and training. |
|
 |
Stephen KasayChief Information OfficerMr. Kasay has over twenty years of experience providing direction to information technology (IT) departments in global pharmaceutical companies and clinical research organizations. His accomplishments include the strategic assessment and consolidation of data, the successful implementation of software and infrastructure assets to enhance productivity, the establishment of global IT governance processes, and the development of relationships and communication practices with business partners to continually improve efficiencies and client service. In his role, Mr. Kasay has global responsibility for the Company’s corporate information technology function including strategy development and execution and optimization of the Company’s technology infrastructure, software and data assets. |
|
 |
Dalvir Gill, PhDPresident, Late Stage DevelopmentDr. Gill has more than 20 years of experience in international clinical research. In his current position, he has overall responsibility for PharmaNet Phase ll to lV services. Prior to PharmaNet, Dr. Gill spent 9 years in various leadership roles at Rhone-Poulenc Rorer (RPR, now Sanofi Aventis) in the United States and Europe. During his tenure at RPR, he played a key role in the submission of a number of successful regulatory filings and also held positions in Process Improvement and Corporate Marketing. |
|
 |
Riaz BandaliPresident, Early Stage DevelopmentMr. Bandali has more than fifteen years of senior management, strategy development, acquisition and divestment, and operations leadership experience in the clinical research and life sciences industries. Before joining PharmaNet, Mr. Bandali served as Senior Vice President, Strategy and Business Development at AB Sciex and Molecular Devices. Mr. Bandali has also held various positions within MDS, including that of Vice President and General Manager of Global Early Stage Development. In his role at PharmaNet, Mr. Bandali is responsible for the leadership of the company’s early stage clinical development business which includes Phase I clinics and bioanalytical laboratories. |
|
 |
Robert Reekie, FFPMChief Operating Officer, Late Stage DevelopmentDr. Reekie has more than 25 years of industry experience. In positions with Boots Pharmaceuticals, Knoll, DAR, and two major CROs, he provided medical support for commercial groups in both ethical pharmaceuticals and consumer medicines. At PharmaNet, Dr. Reekie provides therapeutic expertise in cardiovascular medicine, rheumatology, depression, analgesia, hospital products, and consumer medicines, including those for dental care, ophthalmology, and cough/cold. In addition, he provides specialized expertise in the design and management of clinical development plans and protocols; and the logistics, feasibility, and implementation of European trials according to the EU Clinical Trial Directive. |
|
